Interactions of dirithromycin with human polymorphonuclear leukocytes

W L Hand1, D L Hand

  • 1Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30303.

Insights

Dirithromycin, a macrolide antibiotic, is highly concentrated in human phagocytic cells (polymorphonuclear leukocytes). This prolonged retention may enhance drug delivery to infection sites and aid in bacterial killing.

Area of Science:

  • Pharmacology
  • Microbiology
  • Cell Biology

Background:

  • Macrolide antibiotics exhibit high tissue concentrations.
  • Certain macrolides concentrate within phagocytic cells.
  • Dirithromycin is a novel macrolide antibiotic.

Purpose of the Study:

  • To investigate the interaction between dirithromycin and human polymorphonuclear leukocytes (PMNs).
  • To determine dirithromycin's cellular uptake, retention, and impact on PMN function.

Main Methods:

  • Utilized radiolabeled dirithromycin and velocity-gradient centrifugation to quantify PMN uptake (C/E ratio).
  • Assessed uptake dependency on cell viability, temperature, pH, and microbial particle ingestion.
  • Evaluated dirithromycin's effect on PMN respiratory burst and bacterial killing.

Main Results:

  • Dirithromycin was avidly accumulated by PMNs, with C/E ratios reaching 35 at 2 hours.
  • Uptake was dependent on cell viability, temperature, and pH (optimum 8.6).
  • Dirithromycin exhibited slow efflux from PMNs and inhibited the respiratory burst but enhanced Staphylococcus aureus killing.

Conclusions:

  • Dirithromycin demonstrates significant accumulation and prolonged retention within human PMNs.
  • These cellular interactions suggest a potential role in delivering antibiotics to infection sites and augmenting host defense mechanisms.
  • Dirithromycin's effects on PMN function may contribute to both intra- and extracellular bacterial killing.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...